echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Dupixent receives FDA priority review and is expected to gain new indications

    Dupixent receives FDA priority review and is expected to gain new indications

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, Regeneron and Sanofi jointly announced that the U.


    Eosinophilic esophagitis is a chronic, progressive type 2 inflammatory disease that damages the esophagus, preventing it from working properly


    Dupixent is a fully humanized monoclonal antibody that inhibits the signaling of IL-4 and IL-13 proteins


    ▲ The mechanism of action of Dupixent (Image source: Sanofi official website)

    This sBLA is supported by two Phase 3 clinical trials, as well as data from a long-term extension trial


    The companies plan to file regulatory applications around the world in 2022 to expand the use of Dupixent


    References:

    [1] FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.